COMMUNIQUÉS West-GlobeNewswire

Xenon Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
– Phase 3 azetukalner X-TOLE2 FOS study patient recruitment expected to complete in the next few months with topline data anticipated in early 2026 – Phase 3 azetukalner X-NOVA3 MDD and Phase 3 BPD studies on track to [...]
Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2 study for NDV-01 [...]
Stereotaxis Reports 2025 First Quarter Financial Results
12/05/2025
ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the first [...]
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors
12/05/2025
JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS , DRTSW ) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that [...]
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results
12/05/2025
Completed enrollment in Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) Top-line MaGic results anticipated in September 2025 to be the first of three catalysts for the DNTH103 neuromuscular [...]
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
Total consideration for the sale of FibroGen China to AstraZeneca now expected to be approximately $185 million, a $25 million increase from initial guidance Net cash held in China at closing now estimated to be [...]
Jasper Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
12/05/2025
REDWOOD CITY, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
12/05/2025
– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 [...]
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/05/2025
SAN DIEGO, May 12, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on May 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option [...]
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
BDC-4182 Phase 1 dose-escalation study now open for enrollment BDC-3042 Phase 1 dose-escalation data presented at AACR 2025 demonstrated a favorable safety profile, dose-dependent biological activity, and monotherapy [...]
Akoya Biosciences Reports First Quarter 2025 Financial Results
12/05/2025
MARLBOROUGH, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company ® , today announced its financial results for the first quarter ending March 31, 2025. “ [...]
Sana Biotechnology to Present at the BofA Securities 2025 Healthcare Conference
12/05/2025
SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation [...]
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for AVMAPKI™FAKZYNJA™ CO-PACK
12/05/2025
LOUISVILLE, Ky., May 12, 2025 (GLOBE NEWSWIRE) -- Onco360 ® , the nation’s leading independent specialty pharmacy, has been selected as a national pharmacy partner by Verastem Oncology for AVMAPKI ™ FAKZYNJA ™ CO-PACK ( [...]
LifeMD to Participate in Three Investor Conferences During May
12/05/2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following investor conferences [...]
Cue Biopharma Reports First Quarter 2025 Financial Results and Recent Business Highlights
12/05/2025
Announced Boehringer Ingelheim strategic collaboration and license agreement for CUE-501, including an upfront payment of $12 million and ~$345 million in potential milestone payments Raised gross proceeds of ~$20 [...]
Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
12/05/2025
Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC Expansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma patients with EGFR [...]
Maravai Lifesciences Reports First Quarter 2025 Financial Results
12/05/2025
SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today [...]
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
12/05/2025
Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Sup porting Potential Best-in- [...]
ProKidney Reports First Quarter 2025 Financial Results and Business Highlights
12/05/2025
Full data from Group 1 in the Phase 2 REGEN-007 study expected in Q2 2025 FDA previously confirmed in a Q4 2024 Type B meeting that the accelerated approval pathway is available for rilparencel; additional details on [...]

Pages